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Abstract
Background: In this study, we examined the efficacy and safety of a once-daily dosage schema of colchicine
compared with a twice-daily dosage schema in pediatric patients with familial Mediterranean fever (FMF).
Methods: In this 24-week, multicenter, randomized controlled noninferiority trial, pediatric patients newly
diagnosed with FMF carrying a homozygous or compound heterozygous mutation and not receiving any
treatment were included. Patients were randomly assigned using a block randomization method to receive
treatment with a once- or twice-daily dosage. Clinical and laboratory characteristics and medication side effects
were recorded and compared between groups. The study was carried out in compliance with Good Clinical
Practice and the Consolidated Standards for Reporting of Trials (CONSORT) statement.
Results: A total of 92 patients were selected, and 79 patients completed the study. There were 42 patients in the
once-daily dosage group and 37 in the twice-daily dosage group. The results indicated that the once-daily dosage
was not inferior to the twice-daily dosage regarding decrease in attack frequency and duration as well as
improvement in clinical findings and Mor severity scores. Alterations in laboratory findings indicating inflammation,
such as erythrocyte sedimentation rate, C-reactive protein, and serum amyloid A, were similar in both groups. The
rates of drug side effects were similar between the once- and twice-daily dosage groups, implying comparable
safety of colchicine, with the exception of diarrhea, which was slightly higher in the once-daily dosage group.
Conclusions: Using colchicine with either a once- or twice-daily dosage provides similar clinical and laboratory
improvements. Considering both efficacy and safety, colchicine can be prescribed with a once-daily dosage.
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Background
Familial Mediterranean fever (FMF) is the most frequent
autoinflammatory disease. Attacks are characterized by
periodic fever lasting 12–72 h and serositis, mostly ma-
nifesting as abdominal pain and resolving spontaneously
[1, 2]. The disease is frequently observed, especially in the
Mediterranean region among Sephardic Jews, Armenians,
Turks, and Arabs [3]. The most important complication
of FMF is amyloidosis. Colchicine has been shown to be
the standard treatment of choice. Colchicine also has been
found to be effective in decreasing the prevalence of amyl-
oidosis [4].
Colchicine shows its main effect in mononuclear cells,
where it acts as a microcompartment and keeps colchicine
inside. This provides an intracellular half-life of about 35–
40 h, which is longer than colchicine’s plasma half-life of
about 10–20 h [5, 6]. In addition, it was previously re-
ported that there was no correlation between plasma and
intracellular colchicine concentrations, which was also
shown to be unrelated to daily dosage. Higher plasma
concentrations of colchicine can raise the intracellular
concentration to some extent, and the concentration in
mononuclear cells reaches a plateau [7, 8]. Furthermore, a
pharmacodynamics study showed the effect of colchicine
to be related to colchicine concentration rather than to
plasma concentration in leukocytes [9].
Daily colchicine use has been shown to reduce the fre-
quency, severity, and duration of attacks [10, 11]. Approxi-
mately 10–15 % of patients are resistant to colchicine
treatment. It has been proposed that these patients are in
fact noncompliers rather than nonresponsive to treatment
[12]. Recently, European League Against Rheumatism rec-
ommendations for the management of FMF were pub-
lished. According to the recommendations, colchicine is
given in single or divided doses, depending on the toler-
ance and compliance of the patient [13]. It is also known
that giving a drug in multiple doses reduces the patient’s
adjustment to treatment [14]. For that reason, regular col-
chicine use is important to protect against the most feared
complication associated with its use—amyloidosis—and
reduce mortality. Colchicine can be used up to a dose of
2 mg/day for pediatric patients with FMF. This study was
performed to investigate once- and twice-daily dosage reg-
imens of colchicine in patients requiring a total dose of
1 mg/day [15].
Given that colchicine’s half-life is higher in mononuclear
cells and that the intracellular concentration of colchicine
reaches a plateau regardless of the repeated doses, theoret-
ically there would not be any pharmacokinetic difference
between once- and twice-daily dosage schemas. We there-
fore planned to carry out a randomized controlled trial to
examine the effectiveness of colchicine treatment in con-
trol of disease symptoms, amelioration of laboratory find-
ings, and any drug side effects (i.e., safety).
Methods
Study design
This study was conducted by members of the FMF Arthritis
Vasculitis and Orphan Disease Research in Pediatric
Rheumatology (FAVOR; www.favor.org.tr) study group at
ten centers in Turkey. It was a multicenter randomized
controlled trial of two parallel groups being followed
in pediatric rheumatology outpatient clinics. The ran-
domization was done at the baseline visit, and patients
were assessed in two more visits 3 months apart. The
study was carried out in compliance with Good Clinical
Practice and the Consolidated Standards for Reporting of
Trials (CONSORT) statement [16]. Ethical approval to
conduct the study was obtained from Gulhane Military
Medical Academy. Patients were enrolled between
October 2011 and April 2013.
Participants
Inclusion criteria
Pediatric patients who were newly diagnosed with FMF
according to the criteria of Yalçınkaya et al. [17] or
Livneh et al. [18] and who were confirmed by genetic
analysis to have compound heterozygous or homozygous
mutations were enrolled. Eligible patients between the
ages of 5 and 16 years who weighed 15–30 kg and had
not received any treatment were included. All patients
included were asked by their physicians whether they
had been proven and recorded to have had at least one
FMF attack before enrollment in the study. An FMF at-
tack was defined as presenting with clinical findings of
fever above 38 °C lasting less than 72 h and accompan-
ied by abdominal pain, chest pain, erysipelas such as ery-
thema and/or swelling in the joints, and laboratory
findings demonstrating an acute phase response.
Exclusion criteria
We excluded patients with a major congenital malforma-
tion; a risk of pregnancy; chronic diseases such as organ
transplant, hepatic disorder, chronic kidney disease,
amyloid A amyloidosis, and thyroid disease; or rheuma-
tologic disorders other than FMF.
Baseline assessment
A signed informed consent form was obtained from the
legal guardian of the patients younger than 12 years of
age and from both the patient and the patient’s legal
guardian for patients 12 years of age and older. At the
baseline visit, the patient’s medical history and com-
plaints about the disease were questioned, and the dis-
ease features in the 6 months before admission were
recorded. A physical examination and laboratory tests
were performed at each visit. In the following visits, any
disease attacks or findings due to colchicine treatment
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since the last visit were questioned and physical examin-
ation and laboratory analysis were made.
Interventions
Dosage protocol and data collection
The once-daily dosage group was given colchicine once
daily at 8:00 a.m., and the twice-daily dosage group re-
ceived the treatment at 8:00 a.m. and 8:00 p.m. Patients
were asked to visit the hospital once in 3 months for
control and were evaluated in a total of three clinic
visits. At the baseline visit, the patient’s medical history
and complaints about the disease were questioned, and a
physical examination and laboratory tests were per-
formed. In the following visits, any attack or findings
due to colchicine since the last visit were investigated in
addition to the baseline visit. At the baseline and last
visits, disease severity was assessed using the Mor scor-
ing system as modified for pediatric patients [19]. The
assessment of safety and tolerability of the drug was
done in clinical visits every 12 weeks via physical exami-
nations and laboratory tests. Patients were asked to note
any adverse events after starting colchicine treatment and
were questioned about adverse events at all visits. A phys-
ician from each center was chosen to be responsible for
data collection. After each visit, the data were entered into
a web-based registry system at the www.favor.org.tr web-
site. To ensure accurate, complete, and reliable data, the
following procedures were followed: (1) data collection,
encoding, and storage were provided for the centers; (2) a
training session was held to provide instruction on the
protocol; (3) periodic meetings were held with study coor-
dinators; (4) the principal investigator stayed in contact
with the study coordinators by mail, telephone, and/or fax;
and (5) a data manager reviewed and evaluated the data.
Colchicine dosage
The required colchicine dosage was calculated as a total
of 1 mg daily according to an internationally accepted
advisory published by Kallinich et al. [20]. According to
the advisory, patients between 5 and 10 years of age
should receive colchicine 1 mg/day, which was the age
range of our patients in both groups. All patients were
prescribed 0.5-mg colchicine tablets. Patients in the
once-daily dosage group were given two colchicine tab-
lets at 8:00 a.m. The twice-daily dosage group received
one 0.5-mg colchicine tablet at 8:00 a.m. and one 0.5-mg
colchicine tablet at 8:00 p.m. Thus, the total dosage was
given in either one dose or two divided doses.
Laboratory analysis
All samples were collected in attack-free periods. At
each visit, complete blood count, urinalysis, erythrocyte
sedimentation rate (ESR), C-reactive protein (CRP),
blood urea nitrogen, creatinine, alanine aminotransferase
(ALT), and aspartate aminotransferase (AST) tests were
performed. To assess the inflammatory response, white
blood cell (WBC) count, platelet (PLT) count, ESR, serum
CRP, and serum amyloid A (SAA) were measured.
SAA was measured by enzyme-linked immunosorbent
assay using commercial kits (CUSABIO, Wuhan, China) in
accordance with the manufacturer’s instructions. The mini-
mum detectable concentration for SAA was 39 ng/ml.
Measurements were carried out using a Synergy HT micro-
titer plate reader (BioTek Instruments Inc., Winooski, VT,
USA). All the samples were measured in duplicate.
Samples were studied in the laboratory of the depart-
ment of biochemistry and FAVOR inflammation and re-
search laboratories, Gulhane Military Medical Academy.
Alterations in clinical manifestations, laboratory find-
ings, disease severity scores, and findings due to colchi-
cine side effects at each visit in the once- and twice-daily
dosage groups were compared.
Outcomes
The primary objectives of this study were to compare the
effectiveness of once- and twice-daily colchicine dosage reg-
imens regarding control of disease symptoms, reducing dis-
ease severity assessed using the modified Mor scoring
system [21], and laboratory findings indicative of inflamma-
tion, such as ESR, CRP, and SAA. The secondary objective
of the study was to evaluate the safety and tolerability of the
drug and research whether once- and twice-daily dosage
schemas are clinically similar with regard to side effects.
Sample size estimation
A sample size for each arm was calculated as 43 patients
per group with an α of 0.05 and 0.8 power. The noninfe-
riority for the once-daily dosage schema was defined as
a decrease in Mor score and a statistically significant de-
crease in the number and duration of attacks. The ex-
pected decreases in Mor scores were calculated to be
60 % for the twice-daily dosage group and 70 % for the
once-daily dosage group. The noninferiority limit was as-
sumed to be 15 %. The calculated sample sizes were smaller
than the one for Mor score for decreasing the level of num-
ber and duration of attacks. For the safety analysis, clinical
and laboratory adverse events were recorded for both once-
and twice-daily dosage schemas. Researchers recorded and
evaluated the findings after treatment was started and
judged whether they were due to the study drug.
Randomization
Block randomization into two groups was used to select
groups to ensure accumulative balance of participants
between arms. Computer-based block randomization al-
gorithm was used with a block size of 2 and each patient
was assigned to a treatment group with an equal chance
of allocalization.
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Statistical analysis
Data analysis was performed according to the intention-
to-treat principle. The clinical and laboratory findings
before and after colchicine treatments were compared in
the once- and twice-daily dosage groups. The changes in
these parameters between visits and between groups
were compared. Frequencies and percentages were used
as descriptive statistics for categorical variables. To de-
scribe scale variables, mean ± SD and median (min-max)
were calculated. Differences between groups were assessed
by using Student’s t test for variables with normal distribu-
tion and the Mann-Whitney U test for other variables. To
compare continuous variables for three visits, analysis of
variance for repeated measures was used. χ2 tests were ap-
plied to compare discrete variables. p values less than 0.05
were considered significant. IBM SPSS Statistics for
Windows 21.0 software (IBM, Armonk, NY, USA) was
used for analysis of the data [22].
Results
A total of 105 patients were screened for eligibility, and
92 were selected to be included in the study. Two of the
patients were excluded due to developing additional
rheumatologic diseases (one with Henoch-Schönlein
purpura and one with Behçet’s disease). After ran-
domization, there were 45 patients in each group. In the
once-daily dosage group, three patients did not continue
their visits; in the twice-daily dosage group, three pa-
tients refused the treatment and five patients did not
continue their visits. Ultimately, there were 42 patients
in the once-daily dosage group and 37 in the twice-daily
dosage group who completed the study (Fig. 1). The
female-to-male ratios were 21:21 in the once-daily dos-
age group and 18:19 in the twice-daily dosage group.
The participants’ mean ages were 7.9 (±1.96) years in
the once-daily dosage group and 7.78 (±2.06) years in
the twice-daily dosage group. In the once- and twice-
daily dosage groups, the mean ages of disease onset were
5.14 (±2.90) years and 5.05 (±3.04) years, respectively,
and the mean ages at the time of diagnosis were 7.54
(±2.50) years and 7.51 (±2.66) years, respectively
(Table 1). The frequencies of the mutations were as fol-
lows: in the once-daily dosage group, M694V (60 %),
M680I (13 %), and V726A (9 %); in the twice-daily dos-
age group, M694V (55 %), M680I (15 %), and V726A
(10 %). The most frequent clinical symptom at the base-
line visit was abdominal pain in both groups, with rates
of 69 % and 64.9 % in the once- and twice-daily dosage
groups, respectively. Abdominal pain was followed by
fever (66.9 % in the once-daily dosage group, 54.1 % in
the twice-daily dosage group), headache (40.5 % in the
once-daily dosage group, 37.8 % in the twice-daily dos-
age group), and arthralgia (35.7 % in the once-daily dos-
age group, 51.4 % in the twice-daily dosage group).
The results of the comparison of changes in clinical
findings between visits before and after colchicine treat-
ment in the two groups are presented in Table 2. The
duration of attacks was lower in both groups after col-
chicine treatment. The median number of attacks also
declined after colchicine treatment in both groups (p <
0.001 for both groups). After colchicine treatment, a sig-
nificant decrease was observed in both groups for clin-
ical findings frequently seen in patients with FMF, such
as fever (>38 °C), abdominal pain, arthralgia (p ≤ 0.001
for all findings in the once-daily dosage group, p ≤ 0.001
for the twice-daily dosage group), arthritis (p < 0.001 for
the once-daily dosage group, p = 0.003 for the twice-
daily dosage group), and chest pain (p < 0.001 for the
once-daily dosage group, p = 0.002 for the twice-daily
dosage group). Other clinical findings manifesting dur-
ing the disease course, such as malaise, confinement to
bed during attacks, and headache also decreased signifi-
cantly after colchicine treatment started (p < 0.05 for all
findings).
When the changes in consecutive visits were com-
pared, decreases in the duration of attacks (p = 0.794)
and the number of attacks (p = 0.446) were similar in
both groups. There were no differences between the
once- and twice-daily dosage groups when compared re-
garding changes in the following clinical findings: fever
(p = 0.365), abdominal pain (p = 0.623), arthralgia (p =
0.218), arthritis (p = 0.900), and chest pain (p = 0.253) in
consecutive visits. Amelioration of the symptoms mal-
aise (p = 0.731), confinement to bed during attacks (p =
0.586), and headache (p = 0.530) in consecutive clinical
visits were also similar between the once- and twice-
daily dosage groups. The results of these analyses are
presented in Table 2.
Disease severity was assessed using the Mor scoring
system. The mean Mor score of the baseline visit was
3.48 ± 1.13 in the once-daily dosage group, and it was
3.27 ± 1.07 and significantly decreased after the treat-
ment was started in both the once-daily (p = 0.001) and
twice-daily (p = 0.001) dosage groups. The comparison
of changes in mean Mor scores in consecutive visits be-
tween the two groups did not reveal any significant dif-
ference (p = 0.555) (Table 3).
ESR levels (p < 0.001 for the once-daily dosage group,
p = 0.042 for the twice-daily dosage group) and CRP
(p = 0.010 for the once-daily dosage group, p = 0.005 for
the twice-daily dosage group) significantly decreased after
colchicine treatment, while WBC and PLT counts did not
reveal any significant changes. SAA levels were assessed
for inflammation as well. There was a significant decrease
in SAA levels in the once-daily dosage group (p = 0.004)
and the twice-daily dosage group (p = 0.022). Levels of de-
creasing of SAA were similar in both groups after treat-
ment (p = 0.761).
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Safety
After colchicine treatment started, side effects due to
treatment were observed in both groups. Anorexia was
significantly more frequent in both the once-daily (p =
0.006) and twice-daily (p = 0.018) dosage groups after
treatment. Furthermore, the increase in anorexia at
other visits was not significantly different between the
groups (p = 0.545). Diarrhea was significantly higher in
visits after treatment (19 % at the first visit, 2.4 % at the
second visit) in the once-daily dosage group (p = 0.001),
but it was not significantly higher in the twice-daily dos-
age group (p = 0.074) (10.8 % at the first visit, 2.7 % at
the second visit). However, no difference was observed
between the groups regarding changes in the number of
patients with diarrhea before and after treatment (p =
0.403) (Table 4).
Transaminase levels were high in both the once- and
twice-daily dosage groups at the second visit, after col-
chicine treatment was started, although in a small num-
ber of patients in both groups. High ALT levels were
Fig. 1 Flowchart of the patients through the study. A total of 92 patients were eligible for the study. Two of the patients were excluded due to
having additional rheumatologic diseases. After randomization, three patients in the once-daily dosage group and five patients in the twice-daily
dosage group were lost to follow-up. In the twice-daily dosage group, three patients refused treatment
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observed at the first visit in 9.5 % in the once-daily
dosage group and 10.8 % in the twice-daily dosage
group. High AST levels were observed at the first visit
in 14.3 % in the once-daily dosage group and in 19.4 %
in the twice-daily dosage group. At the third visit, both
ALT (7.1 % in the once-daily dosage group and 2.7 %
in the twice-daily dosage group) and AST (11.9 % in
the once-daily dosage group and 14.3 % in the twice-
daily dosage group) had returned to normal ranges in
both groups. No significant difference between the
once- and twice-daily dosage groups was observed for
changes between visits in ALT levels (p = 0.838) or
AST levels (p = 0.573) (Table 5). There was not any
difference between groups regarding complications of
FMF.
Discussion
In our present randomized controlled noninferiority
study, we aimed to compare once- and twice-daily dos-
ages of colchicine in pediatric patients with FMF, with a
focus on improvements in clinical and laboratory find-
ings and drug side effects. Our results indicate that the
groups were similar in these parameters and that disease
severity scores declined with a similar tendency in both
groups, implying clinical amelioration.
Limitations of our study can be stated as follows: The
sample size was less than estimated in both groups; the
duration of follow-up for safety assessment was 24 weeks,
which might not be enough to evaluate the safety of the
drug; and there is a lack of an outcome assessment for
this disease.
Table 2 Within-group and intergroup comparison of clinical findings
Once-daily dosage group (n = 42) Twice-daily dosage group (n = 37)
Baseline First visit Second visit p Valuea Baseline First visit Second visit p Valuea p Valueb
Features of disease
Fever >38 °C, % 66.7 21.4 19 <0.001 54.1 22.2 16.7 0.001 0.272
Duration of attacks,
h (mean ± SD)
48.00 ± 27.25 12.31 ± 25.18 8.4 ± 21.77 <0.001 44.57 ± 31.42 12.35 ± 24.08 5.6 ± 15.13 <0.001 0.711
Number of attacksc 3 (3–10)d 0 (0–1) 0 (0–1) <0.001 3 (4–10)d 0 (0–1) 0 (0–0) <0.001 0.521
Erysipelas-like erythema, % 7.1 0 4.8 0.174 5.4 0 0 0.135 0.383
Skeletal system manifestations
Arthralgia, % 35.7 21.4 4.8 0.001 51.4 24.3 8.1 <0.001 0.376
Arthritis, % 26.2 2.4 2.4 <0.001 24.3 8.1 0 0.003 0.948
Serosal involvement
Abdominal pain, % 69 23.8 21.4 <0.001 64.9 24.3 21.6 <0.001 0.840
Chest pain, % 31 4.8 4.8 <0.001 18.9 2.7 2.7 0.002 0.142
Systemic manifestations
Malaise, % 64.3 26.2 14.3 <0.001 51.4 24.3 21.6 0.002 0.726
Headache, % 40.5 23.8 14.3 0.002 37.8 16.2 10.8 0.002 0.553
Confinement to bed during
attacks, %
42.9 4.8 0 <0.001 37.8 0 2.7 <0.001 0.505
aMedian (min-max)
bp value for within-group comparison of manifestations before and after colchicine treatment
cp value for intergroup comparison of manifestations
dMedian number of attacks in the 6 months before admission
Table 1 Demographic features of once- and twice-daily dosage groups
Characteristic Once-daily dosage group (n = 42) Twice-daily dosage group (n = 37)
Age,a years 7.90 ± 1.96 7.78 ± 2.00
Sex, F/M 21/21 19/18
Age of disease onset,a years 5.14 ± 2.90 5.05 ± 3.04
Age of disease diagnosis,a years 7.54 ± 2.50 7.51 ± 2.66
Consanguinity, % 16.6 16.2
Presence of FMF in family members, % 59.5 62.2
FMF familial Mediterranean fever
aMean ± SD
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The literature contains only 4 randomized, placebo-
controlled clinical trials comprising a total of 57 patients
with FMF treated with colchicine [11, 23–25]. Colchicine
is the main choice of treatment for patients with FMF. It
has been suggested to be prescribed for this disorder in a
twice-daily dosage according to the aforementioned stud-
ies. This is a disadvantage for adjustments to a treatment
that is highly effective in controlling attacks and severe
complications of the disease when used properly, especially
in adolescents, because taking a medicine in multiple doses
brings with it the problem of forgetting to take doses.
The most frequent clinical findings were abdominal
pain and fever in both groups and other clinical manifes-
tations of our patients. Chest pain, myalgia, and arthritis
were frequently seen in our patients with FMF. Within-
group comparisons of these clinical findings revealed
that colchicine provided reductions in the frequency of
attacks, the duration of attacks, and the frequency of the
clinical findings observed. Intergroup comparisons of
improvements in these findings were similar. This indi-
cated that colchicine was effective in controlling disease
symptoms when used in a once-daily dosage as well as
in a twice-daily dosage. Another noteworthy clinical
finding was with regard to headache, which is not gener-
ally mentioned in many studies. Improvement in head-
ache in patients in both groups in visits after colchicine
treatment was started may suggest the contribution of
colchicine to decreasing inflammation in the meninx as
well as other serosal membranes.
To obtain objective data about the response to treat-
ment, we used the severity assessment score developed
by Mor et al. and modified by Ozen et al. as an outcome
index [19, 26]. Both groups had a significant decrease in
Mor severity scores after treatment, and no difference
was detected between the groups regarding the level of
decrease. These results suggest that a once-daily dosage
of colchicine is not inferior to a twice-daily dosage in
controlling disease severity in patients with FMF. In
addition, when we compared the number of attacks and
the durations of attacks with fever, we found a signifi-
cant decrease in these clinical features compared with
the 6-month period before the treatment was initiated.
Although we accepted the Mor scoring system as a non-
inferiority outcome index, it is not validated in pediatric
patients and lacks frequency and duration of attacks as
severity parameters. In fact, these parameters are of im-
portance in the assessment of the efficacy of FMF treat-
ment, and this was stated in the recently developed
criteria for assessment of FMF severity [16].
CRP, ESR, WBC count, and SAA were evaluated. SAA
protein has been shown to increase with other acute
phase reactants as a response to inflammation and is
Table 4 Comparison of clinical and laboratory side effects of colchicine in subsequent visits
Once-daily dosage group (n = 42) Twice-daily dosage group (n = 37)
Baseline First visit Second visit Baseline First visit Second visit p Valuea
Anorexia, % 0 19 16.7 0 10.8 16.2 0.545
Nausea, % 0 2.4 2.4 0 5.4 5.4 0.392
Diarrhea, % 0 19 2.4 0 10.8 2.7 0.403
Abdominal pain, % 0 9.5 11.9 0 10.8 8.1 0.800
Vomiting, % 0 4.8 0 0 8.1 5.4 0.290
Elevated ALT, % 2.4 9.5 7.1 2.7 10.8 2.7 0.838
Elevated AST, % 4.8 14.3 11.9 5.4 19.4 14.3 0.573
ALT alanine aminotransferase, AST aspartate aminotransferase
ap value for the intergroup comparison of drug side effects
Table 3 Comparison of groups according to modified Mor scoring system
Once-daily dosage group (n = 42) Twice-daily dosage group (n = 37)
Mean SD Mean SD
Baseline 3.48 1.13 3.27 1.07
First visit 2.88 0.89 2.78 0.95
Second visit 2.81 0.83 2.76 0.93
p Valuea <0.001b,c,d <0.001b,c,d
p Valuee 0.555
aAnalysis of variance (ANOVA) for repeated measures intragroup analysis
bStatistically significant difference between baseline and first visit
cStatistically significant difference between baseline and second visit
dStatistically significant difference between first and second visits
eANOVA for repeated measures between groups analysis
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referred to as a parameter for follow-up of inflammation
[21, 27]. After colchicine treatment, CRP, ESR, and
WBC levels returned to normal levels, which indicated
decreasing inflammation with the treatment. High SAA
levels were detected at admission to the clinic, and these
levels decreased in both groups after treatment, regard-
less of the dosage schema. These results suggest that
colchicine was effective in reducing inflammation in
pediatric patients with FMF when applied in either a
once- or twice-daily dosage.
Another parameter taken into consideration in com-
paring the once- and twice-daily dosage schemas was
the safety of the drug. Colchicine inhibits intracellular
microtubular formation and thus inhibits mitosis. Most
side effects are due to this inhibition, and they are seen
in cells with a high proliferation rate. Gastrointestinal
system side effects are the most prevalent, especially ab-
dominal pain, diarrhea, nausea, and vomiting. In our
study groups, anorexia, nausea, diarrhea, and abdominal
pain were observed after colchicine treatment. This was
consistent with the literature [20]. Anorexia was the
prominent manifestation in both groups after treatment.
Nausea and abdominal pain complaints did not demon-
strate any significant difference before and after treat-
ment initiated in both groups. Diarrhea was significantly
high in the once-daily dosage group after treatment, but
the increase in the twice-daily dosage group did not
reach statistical significance. However, no patient
dropped out of the study due to chronic diarrhea, as the
diarrhea continued for a maximum of 1 week and none
of the patients were hospitalized for diarrhea treatment.
When we compared the rise in the number of patients
with this complaint, we did not see any difference be-
tween the once- and twice-daily dosage groups. This
suggested the complaint to be irrelevant to dosage
schema.
The half-life of colchicine in plasma is 10–20 h, and it
reaches 40 h in leukocytes, the site of its action [5, 8].
Taking this into consideration, there should not be any
obstacle to the application of colchicine in a once-daily
dosage. Starting from this point in this study, we aimed
to compare once- and twice-daily dosage schemas of
colchicine treatment regarding clinical manifestations,
laboratory findings, and side effect profiles. The results
obtained from this study revealed that application of
once- or twice-daily dosage was not different, consider-
ing the frequency and duration of attacks and other clin-
ical manifestations and laboratory findings such as acute
phase reaction. Moreover, no difference was observed in
manifestations of side effects due to colchicine.
Colchicine is the most effective drug for treatment of
FMF, and it should be used lifelong. During childhood, the
medication is generally provided by parents; in adulthood,
generally problems with adjustment to treatment occur,
especially if the drug is given in divided doses. According
to the results of our present study, a once-daily dosage of
colchicine was as effective as a twice-daily dosage in con-
trolling disease manifestations and improvement in acute
phase reactions. In addition, there was no difference in
drug side effects with either dosing regimen.
Conclusions
This large, multicenter series in a randomized controlled
noninferiority trial gives evidence supporting an already
common practice to give 1 mg of colchicine daily for the
treatment of FMF. Colchicine treatment can be adminis-
trated in a single dose, and there is no difference be-
tween once- and twice-daily colchicine dosage schemas
regarding control of clinical and laboratory manifesta-
tions or severity of the disease. Considering drug side ef-
fects in pediatric patients with FMF, both treatment
schemas are similar, except for diarrhea being slightly
higher in a once-daily dosage.
Abbreviations
ALT: alanine aminotransferase; ANOVA: analysis of variance; AST: aspartate
aminotransferase; CONSORT: Consolidated Standards of Reporting of Trials;
CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; FAVOR: FMF
Arthritis Vasculitis and Orphan Disease Research in Pediatric Rheumatology;
FMF: familial Mediterranean fever; PLT: platelet; SAA: serum amyloid A;
WBC: white blood cell.
Competing interests
The authors declare that they have no competing interests.
Table 5 Comparison of laboratory findings of acute phase reaction in three visits
Once-daily dosage group (n = 42) Twice-daily dosage group (n = 37)
Baseline First visit Second visit Baseline First visit Second visit p Valuea
Leukocytosis, % 11.9 4.8 4.8 8.1 2.7 5.4 0.591
Thrombocytosis, % 4.8 2.4 4.8 5.4 2.7 10.8 0.329
High ESR, % 55.9 12.5 4.2 56.7 22.2 0 0.988
Elevated CRP, % 40.5 21.4 14.3 37.8 13.5 10.8 0.435
SAA,b mg/L 4.86 ± 3.73 3.28 ± 3.40 4.70 ± 3.57 3.28 ± 3.46 0.449
CRP C-reactive protein, ESR erythrocyte sedimentation rate, SAA serum amyloid A
ap value for intergroup comparison of laboratory results
bMean ± SD
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